Free Trial

Reneo Pharmaceuticals Q2 2023 Earnings Report

Reneo Pharmaceuticals Earnings Headlines

Onkure Therapeutics Inc (OKUR)
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
See More Reneo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reneo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reneo Pharmaceuticals and other key companies, straight to your email.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals (NASDAQ:RPHM), a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

View Reneo Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings